LIST OF PATENTS. Patent Number Author ------------- ------ [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION. CONFIDENTIAL TREATMENT REQUESTED Schedule 18.11 PAYMENTS INVOICED TO MATRIA DESCRIPTION INVOICE # $ AMOUNT ----------- --------- -------- Lab Tests 22836 $ 19,065.00 fFN Complete Kit 22906 $ 14,850.00* Lab Tests 22982 $ 17,763.00 Lab Tests 22942 $ 20,584.00 TOTAL OUTSTANDING $ 72,262.00 *INVOICE 22906 = $29,850 LESS PAYMENT $15,000 RECEIVED PAYMENTS INVOICED TO ADEZA DESCRIPTION INVOICE DATE $ AMOUNT ----------- ------------ -------- FedEx Charges December $ 15,446.52 FedEx Charges January $ 13,247.21 FedEx Charges February $ 16,844.73 TOTAL OUTSTANDING $ 45,538.46 THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION. CONFIDENTIAL TREATMENT REQUESTED EXHIBIT A TRANSITION RESPONSIBILITIES Matria Responsibilities Matria shall, during the Transition Period, perform in good faith the following responsibilities with respect to the fFN ELISA Tests and the fFN Rapid Assay Tests, in substantially the same manner and with the same degree of care that it performed such responsibilities during the ninety (90) day period preceding the Effective Date. Matria shall process and fill orders for fFN ELISA Tests and provide customer service and support. Matria shall pay for the fFN ELISA Tests distributed by Matria during the Transition Period in accordance with the payment practices in effect during the ninety (90) day period preceding the Effective Date, except that (i) the price that Matria will pay for the ELISA kits purchased during the Transition Period shall be $[***], (ii) the price per fFN ELISA Test shall be $[***] plus [***]% of all reimbursement amounts in excess of $[***] collected by Matria for such test and (iii) Adeza shall provide to Matria, at Adeza's expense, [***] individual specimen collection kits for each fFN ELISA Test sold to Matria or [***] individual specimen collection kits, whichever is greater. In the event that Matria requires more than [***] individual specimen collection kit...
LIST OF PATENTS. (Patent Applications, Patents, and Legal Equivalents Thereto)
LIST OF PATENTS. No. Description patent Owned or Co- Owned by AMT reference No Date of filing provisional application Patent number [Other] Strategic Partnerships/Licenses Lipoprotein lipase (LPL) variant therapeutics Amsterdam Molecular Therapeutics B.V. AMT-P101 24 June 1999 PCT/CA00/00762 IL-10 gene transfer to peripheral mononuclear cells Amsterdam Molecular Therapeutics B.V. AMT-P102 07 March 2002 PCT/NL03/00170 Treatment of non-alcoholic steatotic hepatitis (XXXX) Amsterdam Molecular Therapeutics B.V. AMT-P103 20 June 2005 PCT/NL05/000446 Improved AAV vectors produced in insect cells Amsterdam Molecular Therapeutics B.V. AMT-P104 20 October 2005 PCT/NL06/050262 Vectors with modified initiation codons for the translation of AAV-Rep78 useful for the production of AAV in insect cells Amsterdam Molecular Therapeutics B.V. AMT-P105 21 June 2006 PCT/NL07/050298 Use of replication machinery for improved protein production Amsterdam Molecular Therapeutics B.V. AMT-P106 19 September 2007 PCT/NL08/050613 Baculovirus vectors comprising repeated coding sequences with different codon biases Amsterdam Molecular Therapeutics B.V. AMT-P107 26 July 2007 PCT/NL08/050512 LIST OF PATENTS No. Description patent Owned or Co- Owned by AMT reference No Date of filing provisional application Patent number [Other] Optimization of expression of parvoviral rep and cap proteins in insect cells Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P108 19 February 2008 PCT/NL90/050076 Parvoviral capsids with incorporated Gly-Ala repeat region Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P109 17 June 2008 PCT/NL09/050352 Porphobilinogen deaminase gene therapy Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P110 29 September 2008 PCT/NL09/050584 Alanine-Glyoxylate aminotransferase therapeutics Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P111 30 January 2009 PCT/NL10/050044 Use of lipoprotein lipase (LPL) in therapy Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P112 18 May 2009 PCT/NL10/050294 Removal of contaminating viruses from AAV preparations Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P113 08 September 2011 11180594.1 61/532,176 Modified snRNA for use in therapy Amsterdam Molecular Therapeutics (AMT) IP B.V. AMT-P116 08 June 2011 PCT/IB11/050584 LIST OF PATENTS No. Description patent Owned or Co- Owned by AMT reference No Date of filing provisional application Patent number [Other] Mutated Rep encoding sequences for use in AAV production Amsterdam Molecular Therapeutic...
LIST OF PATENTS. The parties agree to substitute an English translation for Exhibit A prior to the closing, such list to include not less than all patents described in Exhibit B hereto.
LIST OF PATENTS. Pursuant to Section 9.6.1 of the Agreement, the following Patents that cover the Process are [**] [**] Country/Treaty Patent/Application # Title Filing Date [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Country/Treaty Patent/Application # Title Filing Date [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] EXHIBIT G CONFIDENTIALITY AGREEMENT CONFIDENTIALITY AGREEMENT This Agreement dated 22 March, 2011 (the “Effective Date”), between Ophthotech Corporation, a Delaware corporation (“Ophthotech”) with offices at 0 Xxxxxx Xxxxx, Suite 106, Princeton, New Jersey, 08540, and Agilent Technologies , a Delaware corporation (“Agilent”) with office at 0000 Xxxxxxx Xxxx # 000, Xxxxxxx, XX 00000-0000
LIST OF PATENTS. Technology Patent Title Jurisdiction Filing Date Application Number Status of Patent New scintillation crystal with emission in the green wavelength region In progress n/a n/a n/a n/a Solid State Blue Laser (488nm) for bio-instrumentation In progress n/a n/a n/a n/a Solid-State Ophthalmology laser In progress n/a n/a n/a n/a Solid-State laser for Heart Revascularisation In progress n/a n/a n/a n/a Thin-film waveguide bio-medical laser applications n/a n/a n/a n/a n/a Solid-State UV Laser for TB Treatment) n/a n/a n/a n/a n/a Green Fibre Laser for bio-medical applications n/a n/a n/a n/a n/a Blue 488nm Fibre Laser for bio-instrumentation n/a n/a n/a n/a n/a Light Source for Optical Coherence Tomography n/a n/a n/a n/a n/a 100206/1155/二97 Real-time Stereoscopic Display 3D Stereoscopic Display And System Russia and PCT application August 22, 2003 0000000000 Pending New-generation Photo-detectors for medical imaging applications (e) n/a n/a n/a n/a n/a Combined dedicated PET/MRI n/a n/a n/a n/a n/a 100206/1155/二97 SCHEDULE 2.2(C) LIST OF TRADE MARKS Biophotonic technologies Technology Trademark New scintillation crystal with emission in the green wavelength region n/a Solid State Blue Laser (488nm) for bio-instrumentation n/a Solid-State Ophthalmology laser n/a Solid-State laser for Heart Revascularisation n/a Thin-film waveguide bio-medical Laser. n/a Solid-State UV Laser for TB Treatment n/a Green Fibre Laser for bio-medical application n/a Blue 488nm Fibre Laser for bio-instrumentation n/a Light Source for Optical Coherence Tomography n/a Real-time Stereoscopic Display (f) n/a New-generation Photo-detector for medical imaging (g) n/a Combined dedicated PET/MRI n/a 100206/1155/二97 SCHEDULE 2.2(D)
LIST OF PATENTS. Exhibit C (Adaptimmune Licensed Patent Rights) sets forth a complete and accurate list of all Patents (including all pending Patent applications) existing as of the Execution Date that are Controlled by Adaptimmune and that Cover the Adaptimmune Differentiation Platform or any of the activities as contemplated within the Research Plan as of the Execution Date;
LIST OF PATENTS. Power Spectra Patents PSI has obtained a number of patents to protect its intellectual property rights. PSI currently holds five (5) patents on its BASS(TM) devices. Current BASS patents are:
LIST OF PATENTS. (1) Method of generating a healthcare plan or wellness plan for a member of a group.
LIST OF PATENTS. To RGX’s knowledge, Appendix A sets forth a complete list of all Patents and Patent applications that are owned, controlled by or licensed to RGX as of the Effective Date that are necessary or useful for the rights, licenses and sublicenses to the RGX Technology granted to QLT hereunder;
